Newsroom
Press Center
Jun 1, 2026
Corporate and finance
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
May 7, 2026
Press release
Corporate and finance
Novavax to Participate in BofA Securities 2026 Health Care Conference
May 6, 2026
Corporate and finance
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
Apr 29, 2026
Press release
Corporate and finance
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
Perspectives & Insights
Explore our blog for valuable insights and inspiring stories from our team as we fulfill our vision to spark transformation in global health.
July 22, 2026
Corporate
By Silvia Taylor, Executive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden
June 24, 2026
Corporate
Partnerships
Research & Development
By Elaine O’Hara, EVP, Chief Strategy Officer and Dr. Bob Walker, EVP, Head of Research & Development
In the News
See what others are saying about Novavax.
Fierce Biotech
Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
Washington Business Journal
Novavax’s stock soars on expected revenue jump from big pharma deals
Pharmaceutical Executive
Expanding the Vaccine Landscape with New Technologies: Q&A with Silvia Taylor
Note: This section features articles written by external media outlets and journalists.
About Novavax
We tackle some of the world's most significant health challenges by leveraging our scientific expertise in vaccines and cutting-edge technology platform, including protein-based nanoparticles and Matrix-M® adjuvant.
